No Data
Press Release: McKesson Corporation Reports Fiscal 2025 Second Quarter Results and Raises Full Year Adjusted EPS Guidance
Express News | Mckesson Corp : Leerink Partners Raises Target Price to $667 From $630
McKesson Analyst Ratings
U.S. stock market anomaly | McKesson rose more than 7% in pre-market trading, Q2 fiscal year 25 performance exceeded expectations, increasing share buybacks to $3.2 billion.
Gelonghui November 7th | Pharmaceutical giant MCK.US rose 7.2% to $588.9 before the market. In terms of news, the company's adjusted eps for the second quarter of 2025 was $7.07, exceeding the estimated $6.88, with sales of $93.7 billion, exceeding the estimated $89.33 billion. The company raised its performance expectations for the 2025 fiscal year, demonstrating confidence in sustained solid performance. Additionally, the company raised its full-year share repurchase target from $2.8 billion to $3.2 billion. (Gelonghui)
Barclays Maintains McKesson(MCK.US) With Buy Rating, Raises Target Price to $668
Barclays Remains a Buy on McKesson (MCK)